



Recent Advancements in Malignant Pleural Mesothelioma: Diagnosis, Treatment, and Molecular Mechanisms

Guest Editor:

Dr. Sara Ricciardi

Unit of Thoracic Surgery, Azienda
Ospedaliera San Camillo
Forlanini, Carlo Forlanini
Hospital, Circonvallazione
Gianicolense 87, 00152 Rome,
Italy

Deadline for manuscript
submissions:

15 July 2024

Message from the Guest Editor

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is a dismal and rare disease caused by asbestos exposure. Since asbestos use peaked around 1980 and the latency time to develop MPM is around 20 to 50 years, the number of deaths from MPM in Europe is expected to peak in 2020–2025.

The optimal treatment for mesothelioma remains under debate; moreover, there is no international agreement on the role of surgery with curative intent.

FUTURE: We need to address some open questions:

- What is the role of neoadjuvant treatment?
- Does the immunotherapy revolutionize the approach to MPM as with what happened to NSCLC?
- Which is the best timing for surgery in multimodal treatment?
- Can Artificial Intelligence predict the outcomes of MPM patients?

The aim of this Special Issue is debating and answering the most important controversies about this cruel disease.

